Call Us: (210) 485-1488

12227 Huebner Road, Ste. 110 View Locations

Nov 2

The iStent May Revolutionize the Treatment of Open-Angle Glaucoma

A new device produced by Glaukos is designed to be a minimally invasive treatment for mild to moderate primary open-angle glaucoma. Preliminary studies are looking very promising for this device. All eyes in the study had intraocular pressures (IOPs) of 18 – 30 mm Hg with one medication or 22 – 38 mm Hg after being treated with one medication and the medication was discontinued. The patient’s cup-to-disc ratios were noted to be less than 0.9. In the study, if the pressures rose above 21 mm Hg after surgery, drops were restarted. In this study, each eye received to iStents.

iStent, glaucoma, primary, open, angle,

At 12 months, IOP was reduced by ~43% from baseline. 89% of the eyes treated with the iStent were medication free. 61% of eyes obtained a decrease of at least 40% without need for medication. The vision was maintained after surgery or improved. There was only one adverse event during the study, a small bleed into the anterior chamber of the eye. It was present for about 1 week and resolved by 1 month.

iStent, primary, open, angle, glaucoma

David F. Chang, M.D. of the University of California-San Francisco stated, “The efficacy outcomes are exciting, and the safety data are also encouraging.”

No comments yet.

Add a comment